Azor Biotek has developed an AI-guided platform to design novel small molecules that target RNA/protein biological complexes.
Using our high throughput multiplex imaging system, we use clinically relevant phenotypic training data — the only kind of data that has successfully identified RNA-targeted drugs approved for clinical use.
RNA as drug targets
Our philosophy of what constitutes the targetable transcriptome
The current market for RNA-targeted small molecules is valued over $113-billion, with only four established drug targets. Azor Biotek's innovative approach allows for the design of novel molecules to target any RNA — opening many previously inaccessible avenues for therapeutic development as every disease has multiple unexploited RNA drug targets .
Live zebrafish screens
Early screening in zebrafish selects for therapeutics with high bioactivity, and allows for in vivo quantification of concrete physiological hallmarks such as neuroactivity, neuroplasticity and cardiograms. These screens endogenously provide approximations of the effective dose, PK/Tox and other off-target effects before molecular analysis.
